<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Frelex| neoaptamers</title>
	<atom:link href="https://neoaptamers.com/category/frelex/feed/" rel="self" type="application/rss+xml" />
	<link>https://neoaptamers.com/category/frelex/</link>
	<description>Neoventures Biotechnology Inc.</description>
	<lastBuildDate>Tue, 14 Apr 2026 14:10:56 +0000</lastBuildDate>
	<language>en-CA</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://neoaptamers.com/wp-content/uploads/2024/07/cropped-NeoVentures-Biotechnology-Square-Logo-No-Text-1-32x32.png</url>
	<title>Frelex| neoaptamers</title>
	<link>https://neoaptamers.com/category/frelex/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>How We Avoid Immobilizing Targets with FRELEX</title>
		<link>https://neoaptamers.com/frelex-advantages/</link>
		
		<dc:creator><![CDATA[Gregory Penner]]></dc:creator>
		<pubDate>Wed, 27 Jul 2022 12:37:44 +0000</pubDate>
				<category><![CDATA[Advanced]]></category>
		<category><![CDATA[Frelex]]></category>
		<guid isPermaLink="false">https://neoaptamers.com/?p=2874</guid>

					<description><![CDATA[<p>Designing aptamers for specific targets needs to be done in a way that ensures you are selecting the aptamers that bind to your target while easily getting rid of those sequences that do not. Typically, this is done by immobilizing the target so that aptamers that bind will stick, while those that do not bind&#8230;&#160;<a href="https://neoaptamers.com/frelex-advantages/" rel="bookmark">Read More &#187;<span class="screen-reader-text">How We Avoid Immobilizing Targets with FRELEX</span></a></p>
<p>The post <a href="https://neoaptamers.com/frelex-advantages/">How We Avoid Immobilizing Targets with FRELEX</a> appeared first on <a href="https://neoaptamers.com">neoaptamers</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Designing aptamers for specific targets needs to be done in a way that ensures you are selecting the aptamers that bind to your target while easily getting rid of those sequences that do not. Typically, this is done by immobilizing the target so that aptamers that bind will stick, while those that do not bind get washed away. The big disadvantage to immobilizing targets is that part of the target is removed from selection due to it being attached to the solid support. This is problematic with every target, from small molecules (entirely removing epitopes for binding) to large proteins (potential to affect folding). We have been able to solve this problem by developing the FRELEX platform, which allows for separation of bound aptamers to the target from those that are not bound in a way that neither the target nor aptamer is immobilized on a surface.</p>
<p>&nbsp;</p>
<h3>What is FRELEX?</h3>
<p>The FRELEX platform utilize a library of random short oligonucleotides on a gold chip. These short oligonucleotides act like a ‘lawn’ that the aptamers can ‘sit’ on by hybridization via Watson-Crick pairing. We first select for the aptamer sequences that sit on this lawn without the target being there. The sequences that bound to the surface are removed and then incubated with the target and reintroduced to the lawn on the gold chip. If the aptamer binds to the target, it will not be able to sit on the lawn of oligonucleotides and we are able to isolate those sequences away from the aptamers that are still sitting on the lawn, and therefore not busy binding to the target.</p>
<p>&nbsp;</p>
<p><img class="alignnone" /><img decoding="async" class="alignnone size-medium wp-image-2875" src="https://neoaptamers.com/wp-content/uploads/2022/07/FRELEX-300x102.png" alt="" width="300" height="102" srcset="https://neoaptamers.com/wp-content/uploads/2022/07/FRELEX-300x102.png 300w, https://neoaptamers.com/wp-content/uploads/2022/07/FRELEX.png 624w" sizes="(max-width: 300px) 100vw, 300px" /></p>
<p>&nbsp;</p>
<p>This approach allows us to select for epitopes on the entire target and not have to worry about selecting aptamers that are non-specifically binding to the immobilization surface used. We continue to use FRELEX to select aptamers for small molecules and proteins to ensure that we are designing the best aptamers for the diagnostic or therapeutic application.</p>
<p>&nbsp;</p>
<p>To learn more about the development and ideal applications of FRELEX, <a href="https://neoaptamers.com/contact-us/">get in touch with our team.</a></p>
<div class="saboxplugin-wrap" itemtype="http://schema.org/Person" itemscope itemprop="author"><div class="saboxplugin-tab"><div class="saboxplugin-gravatar"><img decoding="async" src="https://neoaptamers.com/wp-content/uploads/2022/04/IMG_20200710_1111019-scaled.jpg" width="100"  height="100" alt="" itemprop="image"></div><div class="saboxplugin-authorname"><a href="https://neoaptamers.com/author/lbif/" class="vcard author" rel="author"><span class="fn">Gregory Penner</span></a></div><div class="saboxplugin-desc"><div itemprop="description"><p>Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures.  He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.</p>
<p>Connect with Dr. Penner on <a href="https://www.linkedin.com/in/gregory-penner-1284b7a/">LinkedIn</a> or for company updates, follow <a href="https://www.linkedin.com/company/neoventures-biotechnology-inc-/?originalSubdomain=ca">NeoVentures</a>.</p>
<p><a href="https://neoaptamers.com/contact-us/#">Click here to get in touch with our team.</a></p>
</div></div><div class="clearfix"></div><div class="saboxplugin-socials "><a title="Linkedin" target="_blank" href="https://www.linkedin.com/company/neoventures-biotechnology-inc-/" rel="nofollow noopener" class="saboxplugin-icon-grey"><svg aria-hidden="true" class="sab-linkedin" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M100.3 480H7.4V180.9h92.9V480zM53.8 140.1C24.1 140.1 0 115.5 0 85.8 0 56.1 24.1 32 53.8 32c29.7 0 53.8 24.1 53.8 53.8 0 29.7-24.1 54.3-53.8 54.3zM448 480h-92.7V334.4c0-34.7-.7-79.2-48.3-79.2-48.3 0-55.7 37.7-55.7 76.7V480h-92.8V180.9h89.1v40.8h1.3c12.4-23.5 42.7-48.3 87.9-48.3 94 0 111.3 61.9 111.3 142.3V480z"></path></svg></span></a></div></div></div><p><a class="a2a_button_linkedin" href="https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-advantages%2F&amp;linkname=How%20We%20Avoid%20Immobilizing%20Targets%20with%20FRELEX" title="LinkedIn" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_twitter" href="https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-advantages%2F&amp;linkname=How%20We%20Avoid%20Immobilizing%20Targets%20with%20FRELEX" title="Twitter" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_facebook" href="https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-advantages%2F&amp;linkname=How%20We%20Avoid%20Immobilizing%20Targets%20with%20FRELEX" title="Facebook" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_email" href="https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-advantages%2F&amp;linkname=How%20We%20Avoid%20Immobilizing%20Targets%20with%20FRELEX" title="Email" rel="nofollow noopener" target="_blank"></a></p><p>The post <a href="https://neoaptamers.com/frelex-advantages/">How We Avoid Immobilizing Targets with FRELEX</a> appeared first on <a href="https://neoaptamers.com">neoaptamers</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FRELEX III: Aptamarkers</title>
		<link>https://neoaptamers.com/frelex-iii-aptamarkers/</link>
		
		<dc:creator><![CDATA[partyinfrance]]></dc:creator>
		<pubDate>Tue, 11 May 2021 21:31:43 +0000</pubDate>
				<category><![CDATA[Aptamers]]></category>
		<category><![CDATA[Frelex]]></category>
		<guid isPermaLink="false">https://neoaptamers.com/?p=1331</guid>

					<description><![CDATA[<p>“The universe (which others call the Library) is composed of an indefinite, perhaps infinite number of hexagonal galleries.” ― Jorge Luis Borges, quote from The Library of Babel (https://en.wikipedia.org/wiki/The_Library_of_Babel) A library of aptamers is like a library of books. They both contain strings of information in code. For aptamers the code consists of four symbols,&#8230;&#160;<a href="https://neoaptamers.com/frelex-iii-aptamarkers/" rel="bookmark">Read More &#187;<span class="screen-reader-text">FRELEX III: Aptamarkers</span></a></p>
<p>The post <a href="https://neoaptamers.com/frelex-iii-aptamarkers/">FRELEX III: Aptamarkers</a> appeared first on <a href="https://neoaptamers.com">neoaptamers</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="1331" class="elementor elementor-1331" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-f56432a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="f56432a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6cbc152" data-id="6cbc152" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-31e3455 elementor-widget elementor-widget-text-editor" data-id="31e3455" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p><span style="font-weight: 400;">“</span><i><span style="font-weight: 400;">The universe (which others call the Library) is composed of an indefinite, perhaps infinite number of hexagonal galleries</span></i><span style="font-weight: 400;">.” </span></p><p><span style="font-weight: 400;">― Jorge Luis Borges, quote from The Library of Babel (https://en.wikipedia.org/wiki/The_Library_of_Babel)</span></p><p><span style="font-weight: 400;">A library of aptamers is like a library of books. They both contain strings of information in code. For aptamers the code consists of four symbols, the four nucleotides possible at each location. In a book, the code consists of the letters of the alphabet where each letter is possible at each position. Jorge Luis Borges “The Library of Babel” expressed the beautiful idea that a library could exist that was filled with all possible combinations of the code in separate books would be enormous but not infinite. As such all existing books ever written and all books ever to be written would be contained in the library. </span></p><p><span style="font-weight: 400;">An aptamer library is similar in that all possible sequences of a certain length can be contained within a finite number of sequences. But what makes a book interesting, what makes it something other than gibberish and the same for an aptamer sequence, what makes one aptamer sequence useful and another meaningless? In a book the code has to result in words that are arranged in sentences that form paragraphs that express something with meaning. In an aptamer library this meaning is expressed in the shape that the sequence imparts to the molecule. The meaning of this shape is manifested in its ability to bind specifically to another molecule.</span></p><p><span style="font-weight: 400;">How many molecular shapes are there in blood for an aptamer to bind to? How large is the epitopiome?   If we start with one gene = one protein, then we have a base of approximately 20,000 different proteins. To this base we need to add alternative splicing, post-translational modifications, sequence divergence, cleavage due to degradation, alternative folding patterns, complexes with other proteins and complexes with metabolites. Let’s be generous and say that there must be at least 100 different epitopes on average per protein, and 1,000 different protein configurations. This means that the size of the possible epitopiome is 2 x 10</span><span style="font-weight: 400;">9</span><span style="font-weight: 400;">. A naïve aptamer library consists of 1 x 10</span><span style="font-weight: 400;">15</span><span style="font-weight: 400;"> sequences, thus an excess of 50,000 fold over the number of possible molecular shapes in blood. It should be kept in mind that to date only a little over 1,000 human proteins have been quantified. There is so much that remains unknown. </span></p><p><span style="font-weight: 400;">The potential exists within a naïve aptamer library to characterize all the molecules in blood simultaneously. The question is how to unlock this potential. At our company in Paris, NeoNeuro (</span><a href="http://www.neoneuro-aptamers.com"><span style="font-weight: 400;">www.neoneuro-aptamers.com</span></a><span style="font-weight: 400;">) we have applied FRELEX selection with naïve aptamer libraries against a pool of plasma from individuals with a pathology coupled with negative selection against a pool of plasma from individuals without the pathology. FRELEX enables this because it enables selection against molecules in their native free state by obviating the need for target immobilization. This selection process results in the exponential amplification of the copy number of aptamers that bind to molecules that are proportionally more abundant in the pathology affected plasma. As such, the selection process, and in particular the PCR amplification after each selection round normalizes for differences in the abundance of target molecules. With FRELEX we are screening all molecules in blood for their potential utility as biomarkers of a specific disease. </span></p><p><span style="font-weight: 400;">At NeoNeuro we have used this approach to characterize a subset of aptamers that we call Aptamarkers<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> to predict brain amyloid deposition, a key risk factor for Alzheimer’s disease. With financial support from the Alzheimer’s Drug Discovery Foundation, we are currently validating the predictive power of these Aptamarkers<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> on samples from 400 Australian individuals through a collaboration with the AIBL cohort. We are now ready to expand this application into other diseases and welcome enquires at </span><a href="mailto:info@neoneuro-aptamers.com"><span style="font-weight: 400;">info@neoneuro-aptamers.com</span></a><span style="font-weight: 400;">. With the Aptamarker<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> platform we are digitizing the information contained in blood into a quaternary code that can be easily read with next generation sequencing. </span></p><p><span style="font-weight: 400;">The Library of Babel contains so many books that have yet to be written. The idea that all human ideas represent a finite space is somewhat depressing, but fortunately even with the world wide web, we are nowhere near filling this space yet. The same is true for our understanding of human physiology and the subtle mechanisms that have evolved to maintain wellness in the face of entropy and active attacks by pathogens. Tools like FRELEX and the concept of Aptamarkers<img src="https://s.w.org/images/core/emoji/17.0.2/72x72/2122.png" alt="™" class="wp-smiley" style="height: 1em; max-height: 1em;" /> are like discovering a guide to where the meaningful books are in a library filled with unreadable information.</span></p><p><span style="font-weight: 400;"> Please contact us if you are interested in obtaining a library card to help in your search for knowledge. </span></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p><a class="a2a_button_linkedin" href="https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-iii-aptamarkers%2F&amp;linkname=FRELEX%20III%3A%20Aptamarkers" title="LinkedIn" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_twitter" href="https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-iii-aptamarkers%2F&amp;linkname=FRELEX%20III%3A%20Aptamarkers" title="Twitter" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_facebook" href="https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-iii-aptamarkers%2F&amp;linkname=FRELEX%20III%3A%20Aptamarkers" title="Facebook" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_email" href="https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex-iii-aptamarkers%2F&amp;linkname=FRELEX%20III%3A%20Aptamarkers" title="Email" rel="nofollow noopener" target="_blank"></a></p><p>The post <a href="https://neoaptamers.com/frelex-iii-aptamarkers/">FRELEX III: Aptamarkers</a> appeared first on <a href="https://neoaptamers.com">neoaptamers</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>FRELEX: “The concept”</title>
		<link>https://neoaptamers.com/frelex/</link>
		
		<dc:creator><![CDATA[partyinfrance]]></dc:creator>
		<pubDate>Wed, 21 Apr 2021 16:15:30 +0000</pubDate>
				<category><![CDATA[Aptamers]]></category>
		<category><![CDATA[Frelex]]></category>
		<guid isPermaLink="false">https://neoaptamers.com/?p=1298</guid>

					<description><![CDATA[<p>In the M.C. Escher painting, “Reptiles” it is clear how much more information is present in the three-dimensional representation of the lizards versus their two-dimensional counterparts. The three-dimensional lizards are alive, they are bending over and interacting with surfaces. I will argue that the situation is similar with the   development of antibodies or aptamers for&#8230;&#160;<a href="https://neoaptamers.com/frelex/" rel="bookmark">Read More &#187;<span class="screen-reader-text">FRELEX: “The concept”</span></a></p>
<p>The post <a href="https://neoaptamers.com/frelex/">FRELEX: “The concept”</a> appeared first on <a href="https://neoaptamers.com">neoaptamers</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="1298" class="elementor elementor-1298" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-91100d6 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="91100d6" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-06b9081" data-id="06b9081" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-e932f2f elementor-widget elementor-widget-text-editor" data-id="e932f2f" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>In the M.C. Escher painting, “Reptiles” it is clear how much more information is present in the three-dimensional representation of the lizards versus their two-dimensional counterparts. The three-dimensional lizards are alive, they are bending over and interacting with surfaces. I will argue that the situation is similar with the   development of antibodies or aptamers for small molecules. There is information that is being lost in the way we select these ligands.</p><p>Antibodies do not recognize small molecules in their free state, this is referred to as a lack of sufficient antigenicity. The small molecule must be conjugated to a larger molecule in order to enable antibody selection. The same is true with traditional SELEX aptamer selection as the target molecule needed to be immobilized in order to enable the partitioning of bound aptamers from unbound ones. This tethering of the small molecule to a surface decreases the information present in the small molecule. With molecules this loss of information is manifested in the removal of charge groups that could enter into Van der Waals forces or hydrogen bond interactions with nucleotides in aptamers. The conjugation also has the potential to change the distance between atoms and the resonance of forces within the molecule. Bottom line, conjugating a small molecule to a larger ones diminishes what is interesting in the small molecule, it decreases the target molecules ability to interact with an aptamer.</p><p>At NeoVentures we have developed a patented approach to selecting aptamers for small molecules in their free state that we have called FRELEX. The basis of the approach is the potential for all aptamers to hybridize to random 8mers that are immobilized on a surface. We combine aptamers with a free target and expose this mixture to a surface coated with random 8mers. Aptamers that bind to the free target are less likely to hybridize to the 8mers than aptamers that do not bind to the free target. This really is a negative selection in that we select aptamers that bind to the free small molecule target by capturing those that are not bound to the immobilized 8mers.</p><p>FRELEX is used in a manner similar to SELEX. We retain the aptamers that are bound to the free target, PCR amplify them and repeat the selection process. We increase the stringency of selection by repeating the selection process more times within each selection round prior to PCR amplification. Counter selection is introduced by combining the aptamer library with the counter selection target and retaining those sequences that hybridize to the immobilized random 8mers. With this approach we have succeeded in identifying aptamers for molecules less than 1000 daltons in molecular weight.</p><p>The binding affinity of a small molecule to any ligand, antibody or aptamer is more a function of the binding capacity of the small molecule than it is of the ligand. By maintaining the presence of all of the information in the small molecule, especially all of the charge groups we increase the potential binding affinity between the selected aptamers and these targets. In a future blog we will discuss more applications of this breakthrough platform.</p><p>FRELEX succeeds by maintaining the full reality of the target molecules. By allowing the reptiles to escape from his canvas Escher achieves the same effect. The three-dimensional forms of the creatures are alive, more capable of interacting with their environment. With FRELEX we are able to release small molecules from conjugation and allow them to express themselves in their full real world form. This allows us to develop aptamers that bind to the beautiful, real-world form of each molecule.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p><a class="a2a_button_linkedin" href="https://www.addtoany.com/add_to/linkedin?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex%2F&amp;linkname=FRELEX%3A%20%E2%80%9CThe%20concept%E2%80%9D" title="LinkedIn" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_twitter" href="https://www.addtoany.com/add_to/twitter?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex%2F&amp;linkname=FRELEX%3A%20%E2%80%9CThe%20concept%E2%80%9D" title="Twitter" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_facebook" href="https://www.addtoany.com/add_to/facebook?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex%2F&amp;linkname=FRELEX%3A%20%E2%80%9CThe%20concept%E2%80%9D" title="Facebook" rel="nofollow noopener" target="_blank"></a><a class="a2a_button_email" href="https://www.addtoany.com/add_to/email?linkurl=https%3A%2F%2Fneoaptamers.com%2Ffrelex%2F&amp;linkname=FRELEX%3A%20%E2%80%9CThe%20concept%E2%80%9D" title="Email" rel="nofollow noopener" target="_blank"></a></p><p>The post <a href="https://neoaptamers.com/frelex/">FRELEX: “The concept”</a> appeared first on <a href="https://neoaptamers.com">neoaptamers</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>

<!--
Performance optimized by W3 Total Cache. Learn more: https://www.boldgrid.com/w3-total-cache/?utm_source=w3tc&utm_medium=footer_comment&utm_campaign=free_plugin

Page Caching using Disk: Enhanced 

Served from: neoaptamers.com @ 2026-04-19 23:37:36 by W3 Total Cache
-->